SP
Spero Therapeutics, Inc.
SPRO · NASDAQ
$1.17 -2.50% (-$0.03)
1M -4.88%
Market Cap $67.7M
P/E Ratio 9.18x
Div. Yield -
ROE 16.17%
Piotroski F-Score Moderate
6/9Valuation
99 /100
Cheap EV/EBITDA 2.47x
P/S 1.58x
P/B 1.53x
Growth
42 /100
Stable Book val. growth 8.06%
Rev. growth 7.06%
FCF growth N/A
Profitability
87 /100
Strong Net margin 17.18%
Op. margin 14.02%
FCF margin 45.57%
Quality
75 /100
Excellent ROE 16.17%
ROA 13.99%
Asset turnover 0.81x
Debt
100 /100
Low Current ratio 6.12x
Net debt/EBITDA -6.33x
Debt/Equity 0.05x
Stability
12 /100
Unstable Rev. volatility 83.77%
EPS volatility 299.71%
Profitable years 1
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o SPRO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Esther Rajavelu
Employees
25
Headquarters
Cambridge
Prihajajoči dogodki
12 NOV.
Earnings
Upcoming earnings report